Highnoon (HINOON): Non-Essential Drugs Portfolio Offers Fundamental Strength
Highnoon Laboratories Limited is engaged in production, marketing, and distribution of pharma and consumer healthcare products. Company has a market capitalization of PKR 61.6 billion...
Exploring Pakistan’s Pharma Export Potential
The local pharmaceutical industry in Pakistan is currently facing severe demand-related challenges, following pricing deregulation in 2024. Implemented by the Drug Regulatory Authority of Pakistan...
Pharma Volumetric Growth: Addressing Meager Demand
Approval of deregulation of non-essential drugs by the caretaker federal cabinet in February 2024 resulted in a steep jump in sector revenues. During the same...
Meezan Bank: A Case of High Payouts and Projected Capital Gains
When it comes to companies with high payout ratios, Meezan Bank Limited (MEBL) has consistently been amongst the most notable names in recent quarters.
Undervaluation of Urban Real Estate: Consequences for National Exchequer
Federal Board of Revenue (FBR) has reported the tax-to-GDP ratio of 10.4% for the fiscal year 2024/25. This falls slightly short of the 10.6% target...
Debt Buyback Program: Repayment of Rs 1.5 Trillion Public Debt
The Debt Management Office (DMO) took a major stride by executing an early retirement of Rs 500 billion of domestic debt. The amount, which was borrowed from...
Why Local Drugmakers Took Over: A History of Pharma Policy in Pakistan
Deregulation of non-essential drug prices back in early 2024, captivated many retail pharmaceutical industry stakeholders. This helped industry sales cross PKR 1 trillion mark